Biomarker development for Huntington's disease

Drug Discovery Today

Volumn 19, Issue 7, 2014, Pages 972-979

  Andre, Ralph ^a   Scahill, Rachael I ^a   Haider, Salman ^a   Tabrizi, Sarah J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE RECEPTOR; FLUORODEOXYGLUCOSE; HUNTINGTIN; RACLOPRIDE;

BIOCHEMISTRY; COGNITION; DISEASE COURSE; DISEASE MARKER; FUNCTIONAL NEUROIMAGING; HETEROZYGOTE; HUMAN; HUNTINGTON CHOREA; MOTOR PERFORMANCE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; REVIEW; UNIFIED HUNTINGTON DISEASE RATING SCALE; ANIMAL; CLINICAL TRIAL (TOPIC); HUNTINGTON DISEASE; METABOLISM; PROCEDURES;

ANIMALS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; HUNTINGTON DISEASE; NEUROIMAGING;

EID: 84903792001     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.03.002     Document Type: Review

References (54)

1. C.A. Ross, and S.J. Tabrizi Huntington's disease: from molecular pathogenesis to clinical treatment Lancet Neurol. 10 2011 83 98
2. J.S. Paulsen et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study J. Neurol. Neurosurg. Psychiatry 79 2008 874 880
3. S.J. Tabrizi et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data Lancet Neurol. 8 2009 791 801
4. S.J. Tabrizi et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis Lancet Neurol. 10 2011 31 42
5. S.J. Tabrizi et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data Lancet Neurol. 11 2012 42 53
6. S.J. Tabrizi et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data Lancet Neurol. 12 2013 637 649
7. Huntington Study Group Unified Huntington's Disease Rating Scale: reliability and consistency Mov. Disord. 11 1996 136 142
8. N. Bechtel et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease Neurology 75 2010 2150 2160
9. M.J. Say et al. Visuomotor integration deficits precede clinical onset in Huntington's disease Neuropsychologia 49 2011 264 270
10. J.C. Stout et al. Neurocognitive signs in prodromal Huntington disease Neuropsychology 25 2011 1 14
11. K. Duff et al. Frontal behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness J. Neuropsychiatry Clin. Neurosci. 22 2010 196 207
12. E.A. Epping et al. Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study J. Psychiatr. Res. 47 2013 1423 1431
13. L.J. Beglinger et al. Cognitive change in patients with Huntington disease on the Repeatable Battery for the Assessment of Neuropsychological Status J. Clin. Exp. Neuropsychol. 32 2010 573 578
14. J. Lemiere et al. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation - a longitudinal follow-up study J. Neurol. 251 2004 935 942 (Pubitemid 39119311)
15. C. Beste et al. Levels of error processing in Huntington's disease: a combined study using event-related potentials and voxel-based morphometry Hum. Brain Mapp. 29 2008 121 130 (Pubitemid 351294942)
16. E.H. Aylward et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons Neurology 44 1994 823 828 (Pubitemid 24158794)
17. E.H. Aylward et al. Longitudinal change in regional brain volumes in prodromal Huntington disease J. Neurol. Neurosurg. Psychiatry 82 2011 405 410
18. D.S. Majid et al. Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation Mov. Disord. 26 2011 2544 2551
19. E.H. Aylward et al. Onset and rate of striatal atrophy in preclinical Huntington disease Neurology 63 2004 66 72 (Pubitemid 38943780)
20. N.Z. Hobbs et al. Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease Neuroimage 47 2009 1659 1665
21. F. Squitieri et al. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease CNS Neurosci. Ther. 15 2009 1 11
22. H.D. Rosas et al. A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study Mov. Disord. 26 2011 1691 1697
23. H.D. Rosas et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: selective white matter pathology and its relationship to clinical measures Mov. Disord. 21 2006 1317 1325 (Pubitemid 44613279)
24. D. Stoffers et al. Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study Neurology 74 2010 1208 1216
25. I. Bohanna et al. Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits Brain Imaging Behav. 5 2011 171 180
26. N.Z. Hobbs et al. Evaluation of multi-modal, multi-site neuroimaging measures in Huntington's disease: Baseline results from the PADDINGTON study Neuroimage Clin. 2 2012 204 211
27. K.E. Weaver et al. Longitudinal diffusion tensor imaging in Huntington's disease Exp. Neurol. 216 2009 525 529
28. A. Sritharan et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease J. Neurol. Neurosurg. Psychiatry 81 2010 257 262
29. S. Klöppel et al. Functional compensation of motor function in pre-symptomatic Huntington's disease Brain 132 2009 1624 1632
30. M.J. Novak et al. Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease Brain 135 2012 1165 1179
31. R.C. Wolf et al. Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease J. Cereb. Blood Flow Metab. 31 2011 1908 1918
32. P.G. Unschuld et al. Impaired cortico-striatal functional connectivity in prodromal Huntington's disease Neurosci. Lett. 514 2012 204 209
33. R.C. Wolf et al. Longitudinal functional magnetic resonance imaging of cognition in preclinical Huntington's disease Exp. Neurol. 231 2011 214 222
34. A. Ciarmiello et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease J. Nucl. Med. 47 2006 215 222 (Pubitemid 46780885)
35. A. Feigin et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study J. Nucl. Med. 42 2001 1591 1595 (Pubitemid 33131316)
36. D.E. Kuhl et al. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan Ann. Neurol. 12 1982 425 434 (Pubitemid 12006877)
37. A. Feigin et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease Brain 130 2007 2858 2867 (Pubitemid 350033965)
38. N. Pavese et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study Brain 126 2003 1127 1135 (Pubitemid 36522955)
39. N. Pavese et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers Neurobiol. Dis. 37 2010 356 361
40. N. Pavese et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study Neurology 66 2006 1638 1643 (Pubitemid 43964614)
41. M. Politis et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study Hum. Brain Mapp. 32 2011 258 270
42. A. Sturrock et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease Neurology 75 2010 1702 1710
43. S.J. van den Bogaard et al. Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism J. Neurol. 258 2011 2230 2239
44. H.D. Rosas et al. Alterations in brain transition metals in Huntington disease: an evolving and intricate story Arch. Neurol. 69 2012 887 893
45. E.M. Dumas et al. Elevated brain iron is independent from atrophy in Huntington's disease Neuroimage 61 2012 558 564
46. G. Bartzokis et al. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications Neurochem. Res. 32 2007 1655 1664 (Pubitemid 47428858)
47. S.J. van den Bogaard et al. Magnetization transfer imaging in premanifest and manifest Huntington disease Am. J. Neuroradiol. 33 2012 884 889
48. S.J. van den Bogaard et al. Magnetization transfer imaging in premanifest and manifest Huntington disease: a 2-year follow-up Am. J. Neuroradiol. 34 2013 317 322
49. D.W. Weir et al. Development of biomarkers for Huntington's disease Lancet Neurol. 10 2011 573 590
50. C.M. Chen et al. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients Biochem. Biophys. Res. Commun. 359 2007 335 340
51. S.M. Hersch et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG Neurology 66 2006 250 252 (Pubitemid 43970166)
52. B. Borowsky et al. 8OHdG is not a biomarker for Huntington disease state or progression Neurology 80 2013 1934 1941
53. A. Weiss et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression J. Clin. Invest. 122 2012 3731 3736
54. H. Zhang et al. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain Neuroimage 61 2012 1000 1016